ERANKI LABS
Designed and Built in INDIA
PRECISE . THERAPY . SIMPLIFIED
Solid tumors, including Breast, Lung, Liver, and Sarcomas, represent a critical global health challenge. Our initial focus targets the most prevalent indication affecting women worldwide.
High incidence rates indicating a critical need for accessible care.
Estimated lifetime risk for women in India facing the disease.
Traditional surgery leaves scars, requires antibiotics & long recovery.

Eranki Labs has developed a novel dual-imaging, therapy guidance system with smart sensors. Our platform provides precise, non-invasive ablation for solid tumors while acting as an adjuvant to chemotherapy, enhancing the body's anti-tumor immune response.
We design with the patient and provider in mind - delivering smart, sustainable, and superior clinical outcomes.
Completely non-invasive therapy. Eliminates cosmetic scars and reduces infection risk.
True outpatient procedure. Patients can return to their daily lives almost immediately.
Triggers a powerful systemic anti-tumor immune response, attacking distant metastases.
Acts as a force multiplier for chemotherapy, enhancing drug delivery and effectiveness.
Sustainable medical technology designed with minimal consumables and waste.
Significantly more affordable infrastructure (4-5x lower) than MRI-guided systems.
High-Intensity Focused Ultrasound device to ablate/fractionate tumor tissue without invasive surgery.




Assistant Professor
Department of Biomedical Engineering
Indian Institute of Technology Hyderabad
Director of Operations

P.K. Lashmet Chair Professor and Department Head, Biomedical Engineering, Rensselaer Polytechnic Institute

Neuropharmacology
Board Member, Ignite Life Science Foundation